In early trading on Wednesday, shares of a clinical-stage biotechnology company, Lineage Cell Therapeutics Inc (LCTX) jumped as much as 10.10% to $2.73, a price which is above its previous 52-week high of $2.58.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
So What’s Keeping The Stock Alive?
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lineage Cell was kept quiet today, so what’s keeping the stock alive? Perhaps the company didn’t release any press releases or financial information, and that might be the good news.
Read More
- 3 Best Work-From-Home Stocks for Long-term Investment
- Top 3 Cloud Computing Stocks to Watch For in 2021
However, Age-related Macular Degeneration (AMD) with spatial atrophy of Lineage Cell Therapeutics is being in process in a phase 1/2a clinical trial using OpRegen, which has shown preliminary efficacy and tolerability. The ongoing OpRegen analysis is expected to show fresh data this quarter. Another phase I clinical trial of VAC2 for the treatment of non-small cell lung cancer is also scheduled to be concluded by the end of 2021.
Lineage Cell Therapeutics came out in favor of Proposition 14, which passed recently in California. By authorizing the California Institute for Regenerative Medicine (CIRM) to fund up to $5.5 billion in grants to support therapeutic development, medical research, and facilities based on stem cell technologies, this bill will improve patients’ access to groundbreaking stem cell therapy treatments.
In the third quarter of 2020, LCTX was part of the portfolios of 8 hedge funds. Its high for this figure was 13. Lineage Cell Therapeutics’ earnings per share fell shy of expectations in Q3, coming in at -$0.05, against analysts’ expectations of -$0.04.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Analysts’ Viewpoint
Alternatively, Lineage Cell Therapeutics Inc (LCTX) is well-received by Dawson James, as the analyst firm set a price target of $6.00 on October 12, 2020, and has given LCTX a Buy rating.
